Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
Get Alerts ITCI Hot Sheet
Join SI Premium – FREE
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at two upcoming investor conferences:
Jefferies Virtual Healthcare Conference
Wednesday, June 2 at 11:30 am ET
Goldman Sachs 42nd Annual Global Healthcare Conference
Thursday, June 10 at 1:20 pm ET
The live and archived webcasts can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.
Contact:
Intra-Cellular Therapies, Inc.Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations646-440-9333
Burns McClellan, Inc.Lisa Burns[email protected]212-213-0006
Source: Intra-Cellular Therapies Inc.
Source: Intra-Cellular Therapies Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intra-Cellular Therapies (ITCI) PT Raised to $107 at Canaccord Genuity
- Perseus Mining March Quarterly Report
- BioSyent to Attend Planet MicroCap Showcase
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Goldman Sachs, Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!